RECORD // Company

CNS Pharmaceuticals, Inc.

Built 2026-11-21T08:12:14Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • CNS Pharmaceuticals, Inc. · Ctgov · same registered legal name as 'CNS Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001683168-26-008748

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-2,499,0003 months ended 2026-09-3010-Q2026-11-160001683168-26-0087482026-11-21 08:12 UTCReport an error
Interest expense$3,0003 months ended 2026-09-3010-Q2026-11-160001683168-26-0087482026-11-21 08:12 UTCReport an error
Cash and cash equivalents$17,212,000at 2026-09-3010-Q2026-11-160001683168-26-0087482026-11-21 08:12 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001729427
Ticker
CNSP
EIN
822318545
CUSIP
18978H508
Record ID
sx:sec:0001729427

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

30 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
State of incorporationNV2026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
Business address2100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 770272026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 08:12 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-15,850,5642025-12-3110-K, XBRL NetIncomeLoss2026-11-21 08:12 UTCReport an error
Total assets (at 2025-12-31)$8,623,4662025-12-3110-K, XBRL Assets2026-11-21 08:12 UTCReport an error
Stockholders' equity (at 2025-12-31)$4,522,5562025-12-3110-K, XBRL StockholdersEquity2026-11-21 08:12 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$7,201,0142025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 08:12 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-13,811,1072025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 08:12 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$18,1752025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 08:12 UTCReport an error
Form D total offering amount (D filed 2026-05-19)$22,525,0002026-05-19D2026-11-21 08:12 UTCReport an error
Form D total amount sold (D filed 2026-05-19)$22,525,0002026-05-19D2026-11-21 08:12 UTCReport an error
Form D industry groupPharmaceuticals2026-05-19D2026-11-21 08:12 UTCReport an error
Form D revenue rangeDecline to Disclose2026-05-19D2026-11-21 08:12 UTCReport an error
Form D date of first sale2026-05-042026-05-19D2026-11-21 08:12 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain (filed 2026-10-02)Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under2026-10-02SEC EDGAR 8-K 0001683168-26-007552 (text as filed, excerpt)2026-11-21 08:12 UTCReport an error
8-K Item 5.07, of this Current Report, CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2026 Annual Meeting of Stockholders (filed 2026-10-02)(the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the “2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan by 650,000 shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is 765,061 shares (this includes the 650,000 share increase). For more information about the 2020 Plan and amendments thereto, see the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 21, 2026 (the “Proxy Statement”), the relevant portions of which are incorporated…2026-10-02SEC EDGAR 8-K 0001683168-26-007552 (text as filed, excerpt)2026-11-21 08:12 UTCReport an error
8-K Item 5.07, Submission (filed 2026-10-02)of Matters to a Vote of Security Holders. The Company held its Annual Meeting at 12:00 p.m. ET on September 30, 2026. As of August 10, 2026, the record date for the Annual Meeting, there were 1,461,449 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 668,188, or 45.72%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting. The proposals are described in detail…2026-10-02SEC EDGAR 8-K 0001683168-26-007552 (text as filed, excerpt)2026-11-21 08:12 UTCReport an error
Largest institutional holder #1 (13F as filed): Ikarian Capital, LLC$649,2672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #2 (13F as filed): ADAR1 Capital Management, LLC$334,6002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #3 (13F as filed): Stonepine Capital Management, LLC$198,7192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #4 (13F as filed): BOOTHBAY FUND MANAGEMENT, LLC$64,6452026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD FIDUCIARY TRUST CO$48,8802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$33,4272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #7 (13F as filed): UBS Group AG$6,9832026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #8 (13F as filed): Tower Research Capital LLC (TRC)$3,8192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #9 (13F as filed): BARCLAYS PLC$912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error
Largest institutional holder #10 (13F as filed): BARRETT & COMPANY, INC.$382026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 08:12 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.